Loading...

WuXi AppTec

DB:WX8
Snowflake Description

Excellent balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
WX8
DB
CN¥106B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

WuXi AppTec Co., Ltd. operates as a pharmaceutical and medical device open-access capability and technology platform company worldwide. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print
WX8 Share Price and Events
7 Day Returns
4.5%
DB:WX8
3.1%
Europe Life Sciences
-0.7%
DE Market
1 Year Returns
-
DB:WX8
16.5%
Europe Life Sciences
-7.6%
DE Market
WX8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
WuXi AppTec (WX8) 4.5% 12.4% 1.3% - - -
Europe Life Sciences 3.1% 3.2% 15.6% 16.5% 76.6% 207.7%
DE Market -0.7% -0.5% -3.8% -7.6% 8.3% 11.1%
1 Year Return vs Industry and Market
  • No trading data on WX8.
  • No trading data on WX8.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is WuXi AppTec undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of WuXi AppTec to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for WuXi AppTec.

DB:WX8 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:WX8
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.02 (1 + (1- 25%) (0.94%))
1.019
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.02
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.019 * 5.96%)
6.3%

Discounted Cash Flow Calculation for DB:WX8 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for WuXi AppTec is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:WX8 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 6.3%)
2020 2,159.30 Analyst x3 2,031.35
2021 3,545.97 Analyst x3 3,138.21
2022 3,543.13 Analyst x1 2,949.90
2023 719.00 Analyst x1 563.15
2024 632.10 Est @ -12.09% 465.75
2025 579.06 Est @ -8.39% 401.39
2026 545.44 Est @ -5.81% 355.68
2027 523.65 Est @ -4% 321.24
2028 509.36 Est @ -2.73% 293.96
2029 499.98 Est @ -1.84% 271.45
Present value of next 10 years cash flows CN¥10,792.06
DB:WX8 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥499.98 × (1 + 0.23%) ÷ (6.3% – 0.23%)
CN¥8,255.09
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥8,255.09 ÷ (1 + 6.3%)10
CN¥4,481.80
DB:WX8 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥10,792.06 + CN¥4,481.80
CN¥15,273.87
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥15,273.87 / 1,638.04
CN¥9.32
DB:WX8 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:WX8 represents 0.1198x of SHSE:603259
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.1198x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CNY) x Listing Adjustment Factor
= CN¥ 9.32 x 0.1198
€1.12
Value per share (EUR) From above. €1.12
Current discount Discount to share price of €7.78
= -1 x (€7.78 - €1.12) / €1.12
-596.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of WuXi AppTec is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for WuXi AppTec's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are WuXi AppTec's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:WX8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CNY CN¥1.57
SHSE:603259 Share Price ** SHSE (2019-07-19) in CNY CN¥64.95
Europe Life Sciences Industry PE Ratio Median Figure of 16 Publicly-Listed Life Sciences Companies 39.53x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.75x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of WuXi AppTec.

DB:WX8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SHSE:603259 Share Price ÷ EPS (both in CNY)

= 64.95 ÷ 1.57

41.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • WuXi AppTec is overvalued based on earnings compared to the Europe Life Sciences industry average.
  • WuXi AppTec is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does WuXi AppTec's expected growth come at a high price?
Raw Data
DB:WX8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 41.37x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
16.8%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 11 Publicly-Listed Life Sciences Companies 2.63x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

DB:WX8 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 41.37x ÷ 16.8%

2.47x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • WuXi AppTec is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on WuXi AppTec's assets?
Raw Data
DB:WX8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CNY CN¥11.22
SHSE:603259 Share Price * SHSE (2019-07-19) in CNY CN¥64.95
Europe Life Sciences Industry PB Ratio Median Figure of 35 Publicly-Listed Life Sciences Companies 2.77x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.71x
DB:WX8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SHSE:603259 Share Price ÷ Book Value per Share (both in CNY)

= 64.95 ÷ 11.22

5.79x

* Primary Listing of WuXi AppTec.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • WuXi AppTec is overvalued based on assets compared to the Europe Life Sciences industry average.
X
Value checks
We assess WuXi AppTec's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. WuXi AppTec has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is WuXi AppTec expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is WuXi AppTec expected to grow at an attractive rate?
  • WuXi AppTec's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • WuXi AppTec's earnings growth is expected to exceed the Germany market average.
  • WuXi AppTec's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:WX8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:WX8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 16.8%
DB:WX8 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 18.9%
Europe Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.5%
Europe Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:WX8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:WX8 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 23,225 6,290 4,452 1
2022-12-31 22,172 3,658 3,789 3
2021-12-31 19,310 4,599 3,737 7
2020-12-31 15,186 3,304 2,676 10
2019-12-31 12,168 2,981 2,251 7
DB:WX8 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-03-31 10,241 1,862 2,356
2018-12-31 9,614 1,640 2,261
2018-09-30 9,009 1,589 2,092
2018-06-30 8,509 1,718 1,757
2018-03-31 8,139 1,654 1,181
2017-12-31 7,765 1,794 1,227
2016-12-31 6,116 1,757 975

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • WuXi AppTec's earnings are expected to grow by 16.8% yearly, however this is not considered high growth (20% yearly).
  • WuXi AppTec's revenue is expected to grow by 18.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:WX8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from WuXi AppTec Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:WX8 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 2.31 2.31 2.31 1.00
2021-12-31 2.08 2.36 1.68 7.00
2020-12-31 1.75 2.29 1.29 8.00
2019-12-31 1.30 1.40 1.04 6.00
DB:WX8 Past Financials Data
Date (Data in CNY Millions) EPS *
2019-03-31 1.57
2018-12-31 1.59
2018-09-30 1.53
2018-06-30 1.32
2018-03-31 0.90
2017-12-31 0.94
2016-12-31 0.77

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • WuXi AppTec is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess WuXi AppTec's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
WuXi AppTec has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has WuXi AppTec performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare WuXi AppTec's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • WuXi AppTec has delivered over 20% year on year earnings growth in the past 5 years.
  • WuXi AppTec's 1-year earnings growth exceeds its 5-year average (99.5% vs 34%)
  • WuXi AppTec's earnings growth has exceeded the Europe Life Sciences industry average in the past year (99.5% vs 8.9%).
Earnings and Revenue History
WuXi AppTec's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from WuXi AppTec Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:WX8 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 10,241.39 2,356.34 1,608.71 479.25
2018-12-31 9,613.68 2,260.52 1,479.20 436.53
2018-09-30 9,008.52 2,092.43 1,487.07 267.18
2018-06-30 8,509.09 1,756.55 1,279.71 374.67
2018-03-31 8,138.83 1,180.88 1,209.90 374.67
2017-12-31 7,765.26 1,227.09 1,269.07 305.65
2016-12-31 6,116.13 974.98 1,240.16
2015-12-31 4,883.35 348.97 1,179.22
2014-12-31 4,139.78 461.50 834.82

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • WuXi AppTec has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • WuXi AppTec used its assets more efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • WuXi AppTec's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess WuXi AppTec's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
WuXi AppTec has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is WuXi AppTec's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up WuXi AppTec's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • WuXi AppTec is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • WuXi AppTec's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of WuXi AppTec's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 46.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from WuXi AppTec Company Filings, last reported 3 months ago.

DB:WX8 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 18,888.34 255.00 7,697.11
2018-12-31 18,165.23 135.00 7,885.94
2018-09-30 11,020.82 1,884.13 2,465.32
2018-06-30 10,407.91 1,756.66 4,247.15
2018-03-31 7,067.54 1,835.17 2,142.24
2017-12-31 6,738.01 1,618.19 2,784.82
2016-12-31 6,062.41 489.39 3,948.48
2015-12-31 6,430.12 172.00 2,072.59
2014-12-31 4,902.68 1,077.07 2,617.56
  • WuXi AppTec's level of debt (1.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if WuXi AppTec's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (730.3%, greater than 20% of total debt).
  • WuXi AppTec earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess WuXi AppTec's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. WuXi AppTec has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is WuXi AppTec's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.64%
Current annual income from WuXi AppTec dividends. Estimated to be 0.77% next year.
If you bought €2,000 of WuXi AppTec shares you are expected to receive €13 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • WuXi AppTec's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.48%).
  • WuXi AppTec's dividend is below the markets top 25% of dividend payers in Germany (3.92%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:WX8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:WX8 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.67 1.00
2020-12-31 0.53 2.00
2019-12-31 0.42 3.00
DB:WX8 Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2019-06-25 0.414 0.645

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • WuXi AppTec is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • WuXi AppTec is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of WuXi AppTec's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of WuXi AppTec's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • No need to calculate the sustainability of WuXi AppTec's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess WuXi AppTec's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can WuXi AppTec afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. WuXi AppTec has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of WuXi AppTec's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ge Li
AGE 52
CEO Bio

Dr. Ge Li, Ph.D., serves as Chief Executive Officer of WuXi AppTec Co., Ltd. Dr. Li is a Co-founder of Hua Medicine (Shanghai) Ltd. Dr. Li co-founded WuXi AppTec Co., Ltd. in 2000 and has been its Chairman since 2004 and Chief Executive Officer since 2004. Dr. Li is Founding Partner and Chairman of 6 Dimensions Capital (also known as, Wuxi Healthcare Ventures) since May 2017. He co-founded WuXi AppTec, Inc in 2000 and has been its Chairman and Chief Executive Officer since 2000. Dr. Li co-founded WuXi PharmaTech (Cayman) Inc. in 2000 and has been its Chairman since 2004 and also has been its Chief Executive Officer since 2000. He is a Co-Owner of Ge Li & Ning Zhao Trust. Dr. Li has been an Advisor for WI Harper Group since September 26, 2010. He was the founder of Pharmacopeia, Inc. Dr. Li began his career in 1993 as one of the Founding Scientists at Pharmacopeia, Inc. and held a series of scientific and management leadership positions. Dr. Li spent eight years with Pharmacopeia. He served as Director at Hua Medicine (Shanghai) Ltd. until December 26, 2018. He served as a Director of Adagene (Suzhou) Limited, WuXi AppTec Co., Ltd., Phagelux, Inc, WuXi PharmaTech (Cayman) Inc and WuXi AppTec, Inc. He serves as Member of Advisory Board at MDL Information Systems GmbH. Dr. Li is a Co-Inventor on a number of important patents pertaining to medicinal chemistry and ombinatorial chemistry. He has published numerous articles in peer-reviewed professional journals. Dr. Li's achievements have won him numerous prestigious awards and honors including the Most Innovative Leader of the Chinese Enterprises of 2008 and 2012 Boston Biotech Chief Executive Officers Conference Life Achievement Award. He was named as one of the 2011 China Healthcare Industry Innovative Leaders, Top Contributors to China's Outsourcing Industry, 2011 BayHelix Lifetime Achievement Award, San Diego Bio-Pharma Achievement Award 2010, The 60 Most Influential People during 60 Years Pharmaceutical Development in China, the 2007 China Top 10 Influential Entrepreneurs, Ernst & Young Entrepreneur of the Year China 2007 Award, 2006 China Top Ten Talents (Science & Technology) Award, Forbes 25 Notable Chinese Americans and many more. In 2005, Dr. Li was featured on the cover page of Red Herring magazine's August 1st issue and honored with Distinguished Entrepreneur Award from Overseas Chinese Affairs Office of The State Council of People's Republic of China, receiving this prestigious award at the Great Hall of the People in Beijing on September 29, 2005. He was named as One of the 25 most influential people in biopharma in 2015. Dr. Li holds a Master's degree and Ph.D. degree in Organic Chemistry from Columbia University in 1993 and a B.S. in Chemistry from Peking University in 1989.

CEO Compensation
  • Insufficient data for Ge to compare compensation growth.
  • Insufficient data for Ge to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the WuXi AppTec management team in years:

2.6
Average Tenure
52
Average Age
  • The tenure for the WuXi AppTec management team is about average.
Management Team

Ge Li

TITLE
Co-Founder
AGE
52

Ed Hu

TITLE
Co-CEO & Executive Director
AGE
56
TENURE
0.9 yrs

Ellis Chu

TITLE
Senior VP & CFO
AGE
48
TENURE
0.5 yrs

Peter Tong

TITLE
Chief Operating Officer
TENURE
1.8 yrs

Shuhui Chen

TITLE
Chief Scientific Officer & Executive VP
AGE
55
TENURE
3.6 yrs

Yao Chi

TITLE
Board Secretary & Executive Director of the Corporate Legal Office
AGE
35
TENURE
3.3 yrs

Ning Zhao

TITLE
Gloal Head of Human Resources
AGE
52
TENURE
8.4 yrs

Xiaozhong Liu

TITLE
Executive VP & Director
AGE
55

Zhaohui Zhang

TITLE
Senior VP of Operations & Director
AGE
49

Jian Li

TITLE
Head of Structural Biology and Executive Director
Board of Directors Tenure

Average tenure and age of the WuXi AppTec board of directors in years:

2.8
Average Tenure
52
Average Age
  • The average tenure for the WuXi AppTec board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ge Li

TITLE
Co-Founder
AGE
52
TENURE
15.5 yrs

Ed Hu

TITLE
Co-CEO & Executive Director
AGE
56
TENURE
3.3 yrs

Ning Zhao

TITLE
Gloal Head of Human Resources
AGE
52

Xiaozhong Liu

TITLE
Executive VP & Director
AGE
55
TENURE
14.5 yrs

Zhaohui Zhang

TITLE
Senior VP of Operations & Director
AGE
49
TENURE
14.5 yrs

Hetong Lou

TITLE
Independent Non-Executive Director
AGE
56
TENURE
2.3 yrs

Yan Liu

TITLE
Independent Non-Executive Director
AGE
46

Jiangnan Cai

TITLE
Independent Non-Executive Director
AGE
61
TENURE
2.3 yrs

Harry Liang

TITLE
Chairman of the Supervisory Committee
AGE
52
TENURE
2.3 yrs

Xiaotong Zhang

TITLE
Independent Non-Executive Director
AGE
50
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
16. Jul 19 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 11. Jul 19 11. Jul 19 -710,840 €7.86 €-5,587,877
16. Jul 19 Sell JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 11. Jul 19 11. Jul 19 -181,500 €7.86 €-1,426,762
16. Jul 19 Sell Highbridge Capital Management, LLC Company 11. Jul 19 11. Jul 19 -250,000 €7.86 €-1,965,237
16. Jul 19 Buy J.P. Morgan Asset Management, Inc. Company 11. Jul 19 11. Jul 19 181,500 €7.86 €1,426,762
15. Jul 19 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 10. Jul 19 10. Jul 19 3,056,900 €7.92 €24,216,549
15. Jul 19 Sell Schroder Investment Management (Hong Kong) Limited Company 10. Jul 19 10. Jul 19 -35,699 €7.92 €-282,644
08. Jul 19 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 03. Jul 19 03. Jul 19 827,417 €8.26 €6,835,843
04. Jul 19 Sell Qatar Investment Authority Company 03. Jul 19 03. Jul 19 -4,970,000 €7.73 €-38,422,126
02. Jul 19 Buy JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 27. Jun 19 27. Jun 19 1,082 €7.74 €8,371
02. Jul 19 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 27. Jun 19 27. Jun 19 427,180 €7.74 €3,304,943
02. Jul 19 Sell J.P. Morgan Asset Management, Inc. Company 27. Jun 19 27. Jun 19 -1,900 €7.74 €-14,700
26. Jun 19 Sell Schroder Investment Management (Hong Kong) Limited Company 24. Jun 19 24. Jun 19 -141,300 €7.41 €-1,046,552
25. Jun 19 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 20. Jun 19 20. Jun 19 415,112 €7.83 €3,248,866
21. Jun 19 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 18. Jun 19 18. Jun 19 356,200 €7.62 €2,713,935
20. Jun 19 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 17. Jun 19 17. Jun 19 769,785 €7.53 €5,794,555
19. Jun 19 Sell Wellington Management Group LLP Company 18. Jun 19 18. Jun 19 -164,305 €7.63 €-1,253,884
18. Jun 19 Buy Wellington Management Group LLP Company 17. Jun 19 17. Jun 19 29,343,721 €7.50 €220,188,820
17. Jun 19 Sell Wellington Management Group LLP Company 14. Jun 19 14. Jun 19 -46,340 €7.36 €-341,009
14. Jun 19 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 11. Jun 19 11. Jun 19 2,254,000 €7.08 €15,951,813
14. Jun 19 Sell JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 11. Jun 19 11. Jun 19 -26,460 €7.08 €-187,260
14. Jun 19 Sell Highbridge Capital Management, LLC Company 11. Jun 19 11. Jun 19 -24,220 €7.08 €-171,408
14. Jun 19 Sell J.P. Morgan Asset Management, Inc. Company 11. Jun 19 11. Jun 19 -2,823,687 €7.08 €-19,983,550
13. Jun 19 Sell UBS Asset Management Company 10. Jun 19 10. Jun 19 -76,860 €6.90 €-530,167
04. Jun 19 Sell UBS Asset Management Company 30. May 19 30. May 19 -1,889,300 €7.07 €-13,357,954
04. Jun 19 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 30. May 19 30. May 19 -2,375,233 €7.03 €-16,704,929
03. Jun 19 Buy J.P. Morgan Asset Management, Inc. Company 29. May 19 29. May 19 1,036,213 €7.09 €7,346,170
31. May 19 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 28. May 19 28. May 19 2,127,160 €7.07 €15,035,648
31. May 19 Buy BlackRock, Inc. Company 28. May 19 28. May 19 5,843,880 €7.08 €41,382,767
23. May 19 Buy Capital Research and Management Company Company 21. May 19 21. May 19 99,260 €6.96 €690,687
20. May 19 Buy J.P. Morgan Asset Management, Inc. Company 15. May 19 15. May 19 532,280 €7.02 €3,733,968
15. May 19 Buy J.P. Morgan Asset Management, Inc. Company 10. May 19 10. May 19 1,045,940 €6.95 €7,268,926
07. May 19 Sell Schroder Investment Management (Hong Kong) Limited Company 03. May 19 03. May 19 -235,200 €7.56 €-1,778,801
12. Apr 19 Sell Schroder Investment Management (Hong Kong) Limited Company 09. Apr 19 09. Apr 19 -327,880 €8.00 €-2,623,969
01. Apr 19 Sell Schroder Investment Management (Hong Kong) Limited Company 27. Mar 19 27. Mar 19 -213,920 €7.57 €-1,619,312
25. Mar 19 Sell J.P. Morgan Asset Management, Inc. Company 20. Mar 19 20. Mar 19 -46,200 €7.21 €-333,207
15. Mar 19 Sell Schroder Investment Management (Hong Kong) Limited Company 12. Mar 19 12. Mar 19 -486,080 €7.15 €-3,475,468
14. Mar 19 Buy J.P. Morgan Asset Management, Inc. Company 11. Mar 19 11. Mar 19 76,458 €7.07 €540,700
07. Mar 19 Buy J.P. Morgan Asset Management, Inc. Company 04. Mar 19 04. Mar 19 495,897 €7.26 €3,599,535
06. Mar 19 Sell Schroder Investment Management (Hong Kong) Limited Company 01. Mar 19 01. Mar 19 -332,920 €6.95 €-2,314,981
05. Mar 19 Sell J.P. Morgan Asset Management, Inc. Company 28. Feb 19 28. Feb 19 -287,560 €6.93 €-1,992,857
22. Jan 19 Buy Schroder Investment Management (Hong Kong) Limited Company 17. Jan 19 17. Jan 19 189,980 €5.50 €1,045,214
18. Jan 19 Buy Wellington Management Group LLP Company 17. Jan 19 17. Jan 19 118,020 €5.51 €650,034
14. Jan 19 Sell J.P. Morgan Asset Management, Inc. Company 09. Jan 19 09. Jan 19 -478,940 €5.38 €-2,577,921
14. Jan 19 Sell Morgan Stanley, Investment Banking and Brokerage Investments Company 09. Jan 19 09. Jan 19 -24,839,640 €5.43 €-134,931,478
11. Jan 19 Sell Wellington Management Group LLP Company 09. Jan 19 09. Jan 19 -29,680 €5.39 €-159,905
09. Jan 19 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 04. Jan 19 04. Jan 19 1,367,380 €5.34 €7,305,211
08. Jan 19 Buy J.P. Morgan Asset Management, Inc. Company 03. Jan 19 03. Jan 19 1,288,000 €5.44 €7,003,775
07. Jan 19 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 02. Jan 19 02. Jan 19 361,760 €5.44 €1,969,162
31. Dec 18 Sell J.P. Morgan Asset Management, Inc. Company 24. Dec 18 24. Dec 18 -251,440 €5.40 €-1,358,241
28. Dec 18 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 21. Dec 18 21. Dec 18 1,050,840 €5.33 €5,599,708
28. Dec 18 Buy Schroder Investment Management (Hong Kong) Limited Company 21. Dec 18 21. Dec 18 203,140 €5.28 €1,072,990
27. Dec 18 Sell FIL Limited Company 20. Dec 18 20. Dec 18 -212,800 €5.37 €-1,142,148
03. Jan 19 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 28. Dec 18 28. Dec 18 750,260 €5.33 €3,997,562
27. Dec 18 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 20. Dec 18 20. Dec 18 1,200,080 €5.33 €6,395,673
21. Dec 18 Sell Morgan Stanley, Investment Banking and Brokerage Investments Company 18. Dec 18 18. Dec 18 -80,242 €5.45 €-437,524
21. Dec 18 Buy Morgan Stanley, Investment Banking and Brokerage Investments Company 18. Dec 18 18. Dec 18 630,000 €5.45 €3,435,094
20. Dec 18 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 17. Dec 18 17. Dec 18 458,174 €5.48 €2,508,589
20. Dec 18 Buy JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 17. Dec 18 17. Dec 18 400,540 €5.48 €2,193,033
20. Dec 18 Sell J.P. Morgan Asset Management, Inc. Company 17. Dec 18 17. Dec 18 -400,540 €5.48 €-2,193,033
20. Dec 18 Buy J.P. Morgan Asset Management, Inc. Company 17. Dec 18 17. Dec 18 168,000 €5.48 €919,832
19. Dec 18 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 14. Dec 18 14. Dec 18 300,720 €5.49 €1,651,124
19. Dec 18 Sell J.P. Morgan Asset Management, Inc. Company 14. Dec 18 14. Dec 18 -312,480 €5.49 €-1,715,693
19. Dec 18 Buy J.P. Morgan Asset Management, Inc. Company 14. Dec 18 14. Dec 18 772,380 €5.49 €4,240,806
15. Dec 18 Buy Wellington Management Group LLP Company 13. Dec 18 13. Dec 18 5,263,020 €5.40 €28,433,628
18. Dec 18 Sell Wellington Management Group LLP Company 14. Dec 18 14. Dec 18 -9,520 €5.49 €-52,311
18. Dec 18 Buy Wellington Management Group LLP Company 14. Dec 18 14. Dec 18 782,600 €5.49 €4,300,245
X
Management checks
We assess WuXi AppTec's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. WuXi AppTec has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

WuXi AppTec Co., Ltd. operates as a pharmaceutical and medical device open-access capability and technology platform company worldwide. It offers pharmaceutical discovery services across the drug discovery process; laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, toxicology, and testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development; services and site management organization; clinical development services include project planning; clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CMO/CDMO services; and administrative services, as well as sells scrap materials. The company was founded in 2000 and is headquartered in Shanghai, China.

Details
Name: WuXi AppTec Co., Ltd.
WX8
Exchange: DB
Founded: 2000
CN¥13,745,799,431
1,638,043,314
Website: http://www.wuxiapptec.com
Address: WuXi AppTec Co., Ltd.
288 Fute Zhong Road,
Waigaoqiao Free Trade Zone,
Shanghai,
200131,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SHSE 603259 Domestic Shares Shanghai Stock Exchange CN CNY 08. May 2018
XSSC 603259 Domestic Shares Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect CN CNY 08. May 2018
SEHK 2359 Foreign Shares-Foreign Listed The Stock Exchange of Hong Kong Ltd. HK HKD 13. Dec 2018
DB WX8 Foreign Shares-Foreign Listed Deutsche Boerse AG DE EUR 13. Dec 2018
SHSC 2359 Foreign Shares-Foreign Listed Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect HK HKD 13. Dec 2018
SZSC 2359 Foreign Shares-Foreign Listed The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect HK HKD 13. Dec 2018
Number of employees
Current staff
Staff numbers
18,163
WuXi AppTec employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/20 23:47
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/19
Last earnings filing: 2019/04/30
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.